Homepage > Company > Media > Pharma News > 2022 > Galapagos Acquires CellPoint and AboundBio for Over $250 Million

Galapagos Acquires CellPoint and AboundBio for Over $250 Million

Galapagos has inked purchase deals with two biotech companies, CellPoint and AboundBio, aimed at developing chimeric antigen receptor (CAR)-T therapies.

The acquisition deal with CellPoint includes an upfront payment of over $131 million and potential milestone payments of up to $105 million. The AboundBio purchase is priced at $14 million.

CellPoint has developed a 6-day manufacturing process that allows for a one-week vein-to-vein time compared to over one month with current CAR-T manufacturing methods. A first proprietary CD19 CAR-T investigational therapy is currently in phase 1/2a trials to assess the decentralized point-of-care production model.

With the acquisition of AboundBio, Galapagos will gain access to the company’s antibody technology to help develop next-generation CAR-Ts and bispecific antibodies.

Galapagos NV

Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins. In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration.

June 24, 2022

https://www.fdanews.com/

Read also

FDA approves AstraZeneca’s FASENRA for asthma in children

The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.

Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.